Ecubectedin is under clinical development by Pharma Mar and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ecubectedin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ecubectedin overview

Ecubectedin (PM-14) is under development for the treatment of solid tumors like breast tumor, epithelioid hemangioendothelioma, dedifferentiated sarcoma, soft tissue sarcoma and gastric tumor, esophageal cancer, adenocarcinoma of the gastroesophageal junction, pancreatic cancer, ductal carcinoma, bile duct cancer (cholangiocarcinoma), hepatocellular carcinoma, colorectal cancer, peripheral nerve sheath tumor, fibrosarcoma, pleomorphic liposarcoma, pleomorphic rhabdomyosarcoma, angiosarcoma, head and neck cancer, neuroendocrine gastroenteropancreatic tumors (GEP-NET), non-small cell lung cancer, small-cell lung cancer, sarcomas, liposarcoma, leiomyosarcoma, synovial sarcoma, mixoid liposarcoma, ewing sarcoma, epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, endometrial cancer, cervical cancer, breast cancer, transitional cell carcinoma (urothelial cell carcinoma), renal cell carcinoma, prostate cancer, malignant pleural mesothelioma, adrenocortical carcinoma (adrenal cortex cancer), hormone sensitive breast cancer and, hormone refractory (castration resistant, androgen-independent) prostate cancer. It is administered through intravenous route. The drug candidate is a marine-derived compound.

Pharma Mar overview

Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed products include Yondelis (trabectedin) an antitumor agent indicated for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection; Aplidin (plitidepsin), an anticancer agent for the treatment of multiple myeloma; and Zepzelca (lurbinectedin) for small cell lung cancer. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. It also offers kits used for diagnosis of influenza A and B and respiratory syncytial virus. Its development pipeline includes PM14 for solid tumors, among others. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, and the US, among others. Pharma Mar is headquartered in Madrid, Spain.

For a complete picture of Ecubectedin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.